The MEL-XY3 cell line has already been described (24 (link)). The MEL-XY13 cell line was obtained from a lymph node amelanotic metastasis of an 82-year-old male patient. Both cell lines are HLA-A*0201-positive and have the BRAF V600E mutation, and c-kit (exons 11 and 17) and Nras (exons 2 and 3) sequencing revealed no additional mutations. Both cell lines were grown in melanoma medium (MM) (25 (link)) plus 10% fetal bovine serum (FBS) (Natocor, Carlos Paz, Córdoba, Argentina) at 37°C in air:CO2 (95:5%) humid incubator.
MEL-XY3SUR and MEL-XY13SUR were generated by exposing cancer cells to 10 µM PLX4032, 1 µM GDC-0973 or combined treatment for 5 weeks. Media were changed twice a week. PLX4032 and GDC-0973 were provided by Genentech (South San Francisco, CA, USA).
MEL-XY3SUR and MEL-XY13SUR were generated by exposing cancer cells to 10 µM PLX4032, 1 µM GDC-0973 or combined treatment for 5 weeks. Media were changed twice a week. PLX4032 and GDC-0973 were provided by Genentech (South San Francisco, CA, USA).
